Akoya Biosciences, Inc.

Industrials
Biotechnology: Laboratory Analytical Instruments
www.akoyabio.com

Moat Score
Safety Score

Market Cap $109.60M
PE -2
Debt $75.90M
Cash $13.24M
EV $172.27M
FCF -$48.71M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$57.97M
EBIT	-$50.46M
ROE	-425%
ROA	-39%
FCF	-$48.71M
Equity	$13.63M
Growth Stability	1
PE	-1.89
PB	8.04
P/FCF	-2.25
P/S	1.26
Price/Cash	0.12
Debt/Equity	5.57
Debt/FCF	-1.56
Net Margins	-78%
Gross Margins	58%
Op. Margins	-58%
Sales Growth YoY	-25%
Sales Growth QoQ	-19%
Sales CAGR	25%
Equity CAGR	-44%
Earnings Growth YoY	-18%

Earnings Growth QoQ	-20%
Sales CAGR 5Y	25%
Equity CAGR 5Y	-44%
Earnings CAGR 3Y	22%
Sales CAGR 3Y	22%
Equity CAGR 3Y	-48%
Market Cap	$109.60M
Revenue	$86.82M
Assets	$129.97M
Total Debt	$75.90M
Cash	$13.24M
Shares Outstanding	49.37M
EV	172.27M
Moat Score	1%
Safety Score	51%
Working Capital	48.87M
Current Ratio	2.75
Gross Profit	$50.11M
Shares Growth 3y	18%
Equity Growth QoQ	-39%
Equity Growth YoY	-78%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Akoya Biosciences Inc is an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.

SEC Filings

Direct access to Akoya Biosciences, Inc. (AKYA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Akoya Biosciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Akoya Biosciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Akoya Biosciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Akoya Biosciences, Inc..

Years

Calculation mode

= -$487M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$487M
DCF		-$44M	-$40M	-$37M	-$33M	-$30M	-$27M	-$25M	-$23M	-$21M	-$19M	-$188M
Value	-$487M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-51%	-81%	-94%	-66%	-78%
ROA	-	-21%	-38%	-32%	-39%
ROE	-	-37%	-121%	-118%	-425%

Bad Net Margins (-78.18%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.8	-1.04	-1.38	-1.56
Debt over Equity	-0.71	0.27	1.08	1.4	5.57
Growth Stability	-	-	-	-	1

Good Debt/FCF ratio (-1.56)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Bad Debt/Equity ratio (5.57)

The company is overleveraged and has a bad balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	29%	36%	29%	25%
Earnings YoY growth	-	104%	59%	-10%	-
Equity YoY growth	-	-338%	-52%	-8%	-44%
FCF YoY growth	-	306%	48%	-10%	-